Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Fox Corp Class B (FOX) vs Twist Bioscience Corp (TWST) Price & Performance

Fox Corp Class BTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

Fox Corp Class B vs Twist Bioscience Corp — how do they compare? Fox Corp Class B trades at $56.83 (market cap $25.36B), while Twist Bioscience Corp trades at $160.43 (market cap $10.08B). The key difference: Fox Corp Class B is far larger — about 2.5× Twist Bioscience Corp's market cap, and Fox Corp Class B pays a 1.02% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Twist Bioscience Corp for 27 Days on average.

FOXTWST
Market Cap
$25.36B$10.08B
Volume
886,6204,229,037
Sector
MediaHealth
52-Week High
$67.76$205.00
52-Week Low
$44.39$25.45
Typical Hold Time
75 Days27 Days
Enterprise Value
$28.72B$10.01B
Dividend Yield
1.02%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Fox Corp Class B

FOX trades at $55.98, up 0.72% today, with a bearish technical signal but strong fundamentals. Recent earnings consistently beat estimates, with Q2 2026 EPS of $1.79 surpassing the $1.44 expectation. Revenue grew to $16.30B in 2025, and net income margin expanded to 13.88%. The company maintains solid cash flow, with operating cash flow of $3.32B in 2025. A dividend of $0.29 is scheduled for payment on September 23, 2026.

The stock presents a value opportunity with a P/E of 14.85 below industry averages, supported by analyst consensus price target of $84.75 implying 51% upside. Risks include a projected net cash flow decline to -$1.1B in 2026 and bearish technical indicators. Investor sentiment is mixed amid ongoing regulatory scrutiny of acquisitions, as noted in recent news.

Twist Bioscience Corp

TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.

The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FOX
100% Buy0% Sell
Avg holding period · 75 Days
TWST
37% Buy63% Sell
Avg holding period · 27 Days

Top news

Latest headlines on both assets

About Fox Corp Class B

Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.

Read more on FOX →

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST →